Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Schramm

Allergy & Immunology Boca Raton, FL Medical Doctor

NPI 1972516979 CMS profile 271013

660 Glades Rd, Suite 420, Boca Raton, FL 33431

Open in the dashboard

General payments

$16,944

479 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Schramm of Boca Raton, FL is reported in the CMS Open Payments database as having received $16,944 across 479 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,334 115
2024 General $3,870 80
2023 General $2,983 75
2022 General $1,367 56
2021 General $1,204 45
2020 General $812 40
2019 General $2,375 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Schramm
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Robert Schramm were reported at $4,334. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Robert Schramm Allergy & Immunology median Middle half National median
2019 $2,375 $594 $163–$1,512 $163
2020 $812 $426 $106–$1,233 $114
2021 $1,204 $638 $157–$1,708 $132
2022 $1,367 $790 $205–$1,961 $149
2023 $2,983 $852 $220–$2,147 $160
2024 $3,870 $865 $203–$2,267 $164
2025 $4,334 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $4,486 117 payments
  2. Genzyme Corporation $1,634 34 payments
  3. GlaxoSmithKline, LLC. $1,382 36 payments
  4. Regeneron Healthcare Solutions, Inc. $1,180 40 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $920 36 payments
  6. Amgen Inc. $794 8 payments
  7. OptiNose US, Inc. $485 13 payments
  8. CSL Behring $389 12 payments
  9. Octapharma USA, Inc. $386 13 payments
  10. Pharming Healthcare, Inc. $343 5 payments
  11. Other $4,944 165 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,131 470 payments
  2. Consulting Fee $602 7 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $200 1 payment
  4. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $1,762 40 payments
  2. TEZSPIRE Respiratory $1,504 32 payments
  3. FASENRA Respiratory $1,474 45 payments
  4. DUPIXENT Inflammation And Immunology $965 31 payments
  5. TEZSPIRE Inflammation $794 8 payments
  6. AIRSUPRA $686 16 payments
  7. NUCALA $551 17 payments
  8. Xhance $485 13 payments
  9. FASENRA Respiratory $468 15 payments
  10. HYQVIA $423 19 payments
  11. Other $7,944 285 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

669

Median for Allergy/ Immunology: 449

Drug cost

$233,438

Median for Allergy/ Immunology: $169,700

Branded share of claims

38.9%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 95 $103,734
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 20 $79,659
Breo Ellipta Fluticasone/Vilanterol Brand 37 $23,792
Breyna Budesonide/Formoterol Fumarate Brand 18 $8,466
Epinephrine Generic 46 $6,880
Azelastine Hcl Generic 51 $2,367
Ipratropium Bromide Generic 40 $2,066
Albuterol Sulfate Hfa Albuterol Sulfate Brand 69 $1,900
Levalbuterol Tartrate Hfa Levalbuterol Tartrate Brand 21 $1,112
Fluticasone Propionate Generic 49 $1,038

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$550,209

Of which drugs: $373,021

Medicare patients

285

Average age 77

Services billed

21,877

186 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 62%
Ischemic heart disease 48%
Osteoporosis 32%
Diabetes 27%
Depression 24%
Chronic kidney disease 23%
COPD 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 13 7,065 $211,048
Vaccine for influenza for injection into muscle 90662 Office 27 27 $2,209
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg J7613 Office 30 33 $1

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $564
  • Amgen Inc. $260
$824 — —
DUPIXENT
  • GENZYME CORPORATION $414
  • Regeneron Healthcare Solutions, Inc. $99
$513 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $373
$373 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $226
$226 — —
XOLAIR
  • Genentech, Inc. $125
  • Genentech USA, Inc. $53
  • Novartis Pharmaceuticals Corporation $33
$211 — 7,065

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

479 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record